PNC-27: A Novel Effective Strategy for Targeting the Achilles’ Heel of Multiple Myeloma

Description

The project focuses on using the anticancer peptide PNC-27, which targets the p53 pathway, as a potential therapeutic approach for multiple myeloma (MM). While MM with high-risk features like TP53 deletion has poorer outcomes, PNC-27 has shown promising results in cancer cells, including MM, by inducing cell death. Despite the absence of MDM2 on MM cell membranes, PNC-27 effectively penetrates MM cells’ cytoplasm, exerting potent killing effects. The study aims to understand how PNC-27 affects MM cells’ mitochondrial function, metabolism, and signaling pathways, hypothesizing that it induces mitochondrial damage and oxidative stress, leading to MM cell death. Additionally, the project aims to evaluate PNC-27’s pharmacokinetics, pharmacodynamics, and anti-MM activity in a mouse model, aiming to determine optimal doses and schedules for effective treatment.